US 12,241,128 B2
Methods for early detection of cancer
Stefanie Ann Ward Mortimer, Morgan Hill, CA (US); Amirali Talasaz, Atherton, CA (US); Darya Chudova, San Jose, CA (US); and Helmy Eltoukhy, Atherton, CA (US)
Assigned to Guardant Health, Inc., Palo Alto, CA (US)
Filed by GUARDANT HEALTH, INC., Palo Alto, CA (US)
Filed on Feb. 14, 2024, as Appl. No. 18/441,187.
Application 18/441,187 is a continuation of application No. 18/436,821, filed on Feb. 8, 2024.
Application 18/436,821 is a continuation of application No. 18/457,770, filed on Aug. 29, 2023.
Application 18/457,770 is a continuation of application No. 18/156,890, filed on Jan. 19, 2023, granted, now 11,827,942, issued on Nov. 28, 2023.
Application 18/156,890 is a continuation of application No. 18/047,979, filed on Oct. 19, 2022, granted, now 11,788,153, issued on Oct. 17, 2023.
Application 18/047,979 is a continuation of application No. 17/837,375, filed on Jun. 10, 2022, granted, now 11,519,039, issued on Dec. 6, 2022.
Application 17/837,375 is a continuation of application No. 17/688,762, filed on Mar. 7, 2022, granted, now 11,643,694, issued on May 9, 2023.
Application 17/688,762 is a continuation of application No. 17/507,109, filed on Oct. 21, 2021, granted, now 11,359,248, issued on Jun. 14, 2022.
Application 17/507,109 is a continuation of application No. 17/367,245, filed on Jul. 2, 2021, granted, now 11,345,968, issued on May 31, 2022.
Application 17/367,245 is a continuation of application No. 16/093,916, abandoned, previously published as PCT/US2017/027809, filed on Apr. 14, 2017.
Claims priority of provisional application 62/324,287, filed on Apr. 18, 2016.
Claims priority of provisional application 62/322,773, filed on Apr. 14, 2016.
Claims priority of provisional application 62/322,783, filed on Apr. 14, 2016.
Claims priority of provisional application 62/322,775, filed on Apr. 14, 2016.
Claims priority of provisional application 62/322,784, filed on Apr. 14, 2016.
Claims priority of provisional application 62/322,786, filed on Apr. 14, 2016.
Prior Publication US 2024/0182978 A1, Jun. 6, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01); C12M 1/00 (2006.01); C12M 1/34 (2006.01); C12Q 1/6806 (2018.01); C12Q 1/6855 (2018.01); C12Q 1/6869 (2018.01); G01N 33/574 (2006.01); G16B 20/20 (2019.01); G16B 30/10 (2019.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12M 1/00 (2013.01); C12M 1/34 (2013.01); C12Q 1/6806 (2013.01); C12Q 1/6855 (2013.01); C12Q 1/6869 (2013.01); G01N 33/57407 (2013.01); G16B 20/20 (2019.02); G16B 30/10 (2019.02); G16H 50/20 (2018.01); G16H 50/30 (2018.01); C12Q 2600/118 (2013.01); C12Q 2600/154 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/166 (2013.01)] 20 Claims
 
1. A method for detecting a presence or absence of residual disease in a subject having previously received a treatment for cancer, the method comprising:
(a) ligating adapters to a plurality of cell-free deoxyribonucleic acid (cfDNA) molecules from a blood sample from the subject to produce adapter-ligated polynucleotides, wherein the blood sample was obtained from the subject after the treatment for cancer;
(b) amplifying a plurality of the adapter-ligated polynucleotides to produce amplified polynucleotides;
(c) enriching the amplified polynucleotides for a panel of targeted genomic regions by performing amplification-based enrichment, wherein the panel comprises no more than 20 genomic regions;
(d) sequencing a plurality of enriched cfDNA to generate sequencing data comprising sequencing reads, wherein the sequencing is performed at a depth of at least 50,000 reads per base; and
(e) determining a presence or absence of one or more genetic variants in the cfDNA molecules from the sequencing data to detect the presence or absence of residual disease in the subject.